189 related articles for article (PubMed ID: 8163047)
1. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
Engerman RL; Kern TS; Larson ME
Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
[TBL] [Abstract][Full Text] [Related]
2. Aldose reductase and the development of renal disease in diabetic dogs.
Kern TS; Engerman RL
J Diabetes Complications; 1999; 13(1):10-6. PubMed ID: 10232704
[TBL] [Abstract][Full Text] [Related]
3. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
Judzewitsch RG; Jaspan JB; Polonsky KS; Weinberg CR; Halter JB; Halar E; Pfeifer MA; Vukadinovic C; Bernstein L; Schneider M; Liang KY; Gabbay KH; Rubenstein AH; Porte D
N Engl J Med; 1983 Jan; 308(3):119-25. PubMed ID: 6401351
[TBL] [Abstract][Full Text] [Related]
4. Nerve conduction velocity in dogs is reduced by diabetes and not by galactosemia.
Engerman RL; Kern TS; Larson ME
Metabolism; 1990 Jun; 39(6):638-40. PubMed ID: 2352480
[TBL] [Abstract][Full Text] [Related]
5. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
Tomlinson DR; Moriarty RJ; Mayer JH
Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
[TBL] [Abstract][Full Text] [Related]
6. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
Engerman RL; Kern TS
Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
[TBL] [Abstract][Full Text] [Related]
7. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
Yue DK; Hanwell MA; Satchell PM; Turtle JR
Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
[TBL] [Abstract][Full Text] [Related]
8. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
Kato N; Mizuno K; Makino M; Suzuki T; Yagihashi S
Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
[TBL] [Abstract][Full Text] [Related]
9. Resistance of the diabetic rat nerve to ischemic inactivation.
Jaramillo J; Simard-Duquesne N; Dvornik D
Can J Physiol Pharmacol; 1985 Jul; 63(7):773-7. PubMed ID: 3930062
[TBL] [Abstract][Full Text] [Related]
10. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
11. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
[TBL] [Abstract][Full Text] [Related]
12. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
Kern TS; Engerman RL
Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
[TBL] [Abstract][Full Text] [Related]
13. The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat.
Cameron NE; Leonard MB; Ross IS; Whiting PH
Diabetologia; 1986 Mar; 29(3):168-74. PubMed ID: 3084324
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
[TBL] [Abstract][Full Text] [Related]
15. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
[TBL] [Abstract][Full Text] [Related]
16. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
[TBL] [Abstract][Full Text] [Related]
17. Effect of treating streptozotocin-induced diabetic rats with sorbinil, myo-inositol or aminoguanidine on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve.
Coppey LJ; Gellett JS; Davidson EP; Dunlap JA; Yorek MA
Int J Exp Diabetes Res; 2002; 3(1):21-36. PubMed ID: 11900277
[TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase.
Price SA; Agthong S; Middlemas AB; Tomlinson DR
Diabetes; 2004 Jul; 53(7):1851-6. PubMed ID: 15220210
[TBL] [Abstract][Full Text] [Related]
19. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
[TBL] [Abstract][Full Text] [Related]
20. Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity.
Pfeifer MA
Am J Med; 1985 Nov; 79(5A):18-23. PubMed ID: 3934964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
